Table 1.
Baseline characteristics
| Clopidogrel (n = 577) | Ticagrelor (n = 426) | p value | |
|---|---|---|---|
| Demographics | |||
| Age, years (mean ± SD) | 66.5±9.7 | 66.6±9.4 | 0.87 |
| Female sex | 186 (32.2) | 132 (31.0) | 0.17 |
| BMI, kg/m2 (mean ± SD) | 27.8±4.6 | 27.6±4.5 | 0.54 |
| Medical history | |||
| Hypertension | 401 (69.5) | 296 (69.5) | 1.00 |
| Diabetes mellitus | 162 (28.1) | 108 (25.4) | 0.34 |
| Previous history of MI | 142 (24.6) | 94 (22.1) | 0.35 |
| Previous history of PCI | 137 (23.7) | 88 (20.7) | 0.25 |
| Previous history of CABG | 65 (11.3) | 36 (8.5) | 0.14 |
| Previous bleeding | 91 (15.8) | 77 (18.1) | 0.33 |
| Previous GI bleeding | 38 (6.6) | 25 (5.9) | 0.64 |
| Smoking | |||
| Current smoker | 57 (9.9) | 43 (10.1) | 0.22 |
| Former smoker | 318 (55.1) | 212 (49.8) | 0.22 |
| CCS angina score | |||
| Class I | 28 (5.1) | 35 (8.4) | 0.12 |
| Class II | 328 (59.9) | 257 (61.5) | |
| Clas III | 190 (34.7) | 125 (29.9) | |
| Class IV | 2 (0.4) | 1 (0.2) | |
| Laboratory findings | |||
| Anemia* | 81 (14.0) | 31 (7.3) | 0.001 |
| Hb on arrival, g/L (mean ± SD) | 137.6±12.3 | 141.5±12.1 | <0.001 |
| Platelet count, x109/L (mean ± SD) | 244.4±74.4 | 236.9±66.6 | 0.097 |
| Creatinine, umol/L (mean ± SD) | 91.6±45.9 | 80.7±21.7 | <0.001 |
| eGFR-CG**, mL/min (mean ± SD) | 85.1±36.8 | 91.1±32.0 | 0.009 |
| CKD** (eGFR <45 mL/min), n (%) | 54 (9.8) | 14 (3.5) | <0.001 |
| CKD** (eGFR <60 mL/min), n (%) | 108 (19.6) | 42 (10.4) | <0.001 |
| Medication prior to angiography | |||
| Aspirin | 577 (100.0) | 426 (100.0) | N/A |
| Clopidogrel | 577 (100.0) | 0 (0.0) | N/A |
| Ticagrelor | 0 (0.0) | 426 (100.0) | N/A |
| Warfarin | 42 (7.3) | 27 (6.3) | 0.56 |
| NOAC | 1 (0.2) | 4 (0.9) | 0.17 |
| Statin | 473 (82.0) | 311 (73.0) | 0.001 |
Results are presented as numbers (percentages). SD, standard deviation; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; GI, gastrointestinal; CCS, Canadian cardiovascular Society; Hb, hemoglobin; eGFR, estimated glomerular filtration rate (calculated using the Cockroft-Gault equation); CKD, chronic kidney disease; NOAC, non-vitamin K antagonist oral anticoagulant.
*
Anemia defined as <120 g/L for women and <130 g/L for men.
**
Based on 550 of 577 and 403 of 426 patients respectively, with complete information to calculate eGFR-CG.